Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)

Inclusion Criteria: * Body weight ≥ 40 kg, Body Mass Index (BMI) \< 32.5 kg/m² * Within the five years prior to screening, patients must have been diagnosed with primary IgAN or PMN through renal biopsy, or within one year prior to screening, diagnosed with C3G or IC-MPGN through renal biopsy, accompanied by glomerular C3 deposition; if a renal biopsy has not been previously performed, a renal biopsy must be conducted during the screening period to confirm eligibility criteria. * Participants with IgAN and C3G/IC-MPGN: During the screening period, morning urine UPCR or 24-hour UPCR ≥0.75 g/g or 24-hour UP ≥1 g/day, with the average of two 24-hour UPCR measurements at baseline ≥0.75 g/g; PMN participants: During the screening period, morning urine or 24-hour UP ≥3.5 g/day, with the average of two 24-hour UP measurements at baseline ≥3.5 g/day. * During the screening and baseline periods, eGFR ≥ 30 ml·min-¹·1.73 m-² (using the CKD-EPI formula) * Prior to the first administration, the patient should have received the maximum tolerated dose or the maximum dose recommended in the instructions of an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) for at least 12 weeks, and the dose of the ACEi or ARB should have been stable for at least 4 weeks before the first administration. * Voluntarily receive meningococcal and pneumococcal vaccines at least 2 weeks before the first administration of the investigational drug in accordance with the pr…